|Dr. Shawn Shirazi B.Sc., M.Sc., Ph.D.||Chief Exec. Officer||257.01k||N/A||N/A|
|Ms. Kristina Hachey C.P.A.||CFO & Director||305k||N/A||N/A|
|Dr. Arkady Mandel||Chief Scientific Officer & Director||410k||N/A||N/A|
|Mr. David M. Groves B.A||Pres of World Trade Division||N/A||N/A||N/A|
|Mr. Roger John Dumoulin-White||Director of Bus. Devel.||N/A||N/A||N/A|
|Lori Leach||Marketing & Media Relations Consultant||N/A||N/A||N/A|
|Mr. Vaughn Wyant||Marketing & Media Relations Consultant||N/A||N/A||N/A|
|Dr. Terry Ruch DVM||Equine Medical Consultant||N/A||N/A||N/A|
Theralase Technologies Inc., a clinical stage pharmaceutical company, engages in the research and development of photo dynamic compounds (PDCs) and their associated drug formulations to treat cancer in Canada, the United States, and internationally. The company also designs, develops, manufactures, and commercializes medical laser systems and other technologies for the activation of PDCs; designs, develops, manufactures, and markets patented and proprietary super-pulsed laser technology for the healing of chronic knee pain, as well as for off-label use to heal various nerve, muscle, and joint conditions. The company is developing TLD-1433, which is in Phase II for the treatment of non-muscle invasive bladder cancer (NMIBC). Its products include TLC-1000, TLC-2000, and controllerless series laser technology products for the elimination of pain, reduction of inflammation, and acceleration of tissue healing, as well as TLC-1000 and TLC-2000 accessories; and Theralase therapeutic laser treatments for patients, including pain management, arthritis, wound healing, addiction rehabilitation and weight loss, and anti-aging, as well as companion animals and equine. Theralase Technologies Inc. has a research agreement with the University of Manitoba Medical Microbiology department for the development of a coronavirus vaccine and therapy. The company sells its products to healthcare practitioners. Theralase Technologies Inc. was founded in 1994 and is headquartered in Toronto, Canada.
Theralase Technologies Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.